Impact BioMedical completes merger with Zoar Limited, trading to shift to NYSE American
Impact BioMedical Inc. has successfully completed its merger with Zoar Limited, with the combined entity now trading on the NYSE American under the ticker symbol "ZOAR". The transaction, which was approved by Impact BioMedical's shareholders at a special meeting, resulted in Impact BioMedical becoming a wholly owned subsidiary of PubCo, a Cayman Islands company.
Shareholders of Impact BioMedical received approximately 8.64 million PubCo ordinary shares, representing about 4.80% of the outstanding shares at closing. The delisting of Impact BioMedical's common stock from NYSE American and its suspension of trading will become effective ten days after the filing of Form 25 with the SEC.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
